New Zealand - English - Medsafe (Medicines Safety Authority)

organon (new zealand) limited - alendronate sodium trihydrate 91.37mg equivalent to 70 mg alendronate anhydrous free acid; colecalciferol 140ug equivalent to 5600 iu;   - tablet - 70/140 - active: alendronate sodium trihydrate 91.37mg equivalent to 70 mg alendronate anhydrous free acid colecalciferol 140ug equivalent to 5600 iu   excipient: colloidal silicon dioxide croscarmellose sodium lactose magnesium stearate microcrystalline cellulose - fosamax plus is indicated for the treatment of osteoporosis in select patients where vitamin d supplementation is recommended.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - isotretinoin 0.05%{relative} (2% overage added);   - topical gel - 0.05% w/w - active: isotretinoin 0.05%{relative} (2% overage added)   excipient: butylated hydroxytoluene ethanol hyprolose - isotrex gel is indicated for the topical treatment of mild to moderate acne vulgaris, characterised by papules and pustules.

New Zealand - English - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - atomoxetine hydrochloride 114.3mg equivalent to 100 mg atomoxetine free base - capsule - 100 mg - active: atomoxetine hydrochloride 114.3mg equivalent to 100 mg atomoxetine free base excipient: dimeticone gelatin   iron oxide red   iron oxide yellow   pregelatinised maize starch sodium laurilsulfate   tekprint black sw-9008   tekprint black sw-9010   titanium dioxide   - strattera is indicated for the treatment of attention-deficit/hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older and adolescents.

New Zealand - English - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - atomoxetine hydrochloride 11.43mg equivalent to 10 mg atomoxetine free base - capsule - 10 mg - active: atomoxetine hydrochloride 11.43mg equivalent to 10 mg atomoxetine free base excipient: dimeticone gelatin pregelatinised maize starch sodium laurilsulfate tekprint black sw-9008 tekprint black sw-9010 titanium dioxide - strattera is indicated for the treatment of attention-deficit/hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older and adolescents.

New Zealand - English - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - atomoxetine hydrochloride 20.57mg equivalent to 18 mg atomoxetine free base - capsule - 18 mg - active: atomoxetine hydrochloride 20.57mg equivalent to 18 mg atomoxetine free base excipient: dimeticone gelatin iron oxide yellow pregelatinised maize starch sodium laurilsulfate tekprint black sw-9008 tekprint black sw-9010 titanium dioxide - strattera is indicated for the treatment of attention-deficit/hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older and adolescents.

New Zealand - English - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - atomoxetine hydrochloride 28.57mg equivalent to 25 mg atomoxetine free base - capsule - 25 mg - active: atomoxetine hydrochloride 28.57mg equivalent to 25 mg atomoxetine free base excipient: dimeticone gelatin indigo carmine pregelatinised maize starch sodium laurilsulfate tekprint black sw-9008 tekprint black sw-9010 titanium dioxide - strattera is indicated for the treatment of attention-deficit/hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older and adolescents.

New Zealand - English - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - atomoxetine hydrochloride 45.71mg equivalent to 40 mg atomoxetine free base - capsule - 40 mg - active: atomoxetine hydrochloride 45.71mg equivalent to 40 mg atomoxetine free base excipient: dimeticone gelatin indigo carmine pregelatinised maize starch sodium laurilsulfate tekprint black sw-9008 tekprint black sw-9010 titanium dioxide - strattera is indicated for the treatment of attention-deficit/hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older and adolescents.

New Zealand - English - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - atomoxetine hydrochloride 5.71mg equivalent to 5 mg atomoxetine free base - capsule - 5 mg - active: atomoxetine hydrochloride 5.71mg equivalent to 5 mg atomoxetine free base excipient: dimeticone gelatin iron oxide yellow pregelatinised maize starch sodium laurilsulfate tekprint black sw-9008 tekprint black sw-9010 - strattera is indicated for the treatment of attention-deficit/hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older and adolescents.

New Zealand - English - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - atomoxetine hydrochloride 68.56mg equivalent to 60 mg atomoxetine free base - capsule - 60 mg - active: atomoxetine hydrochloride 68.56mg equivalent to 60 mg atomoxetine free base excipient: dimeticone gelatin indigo carmine iron oxide yellow pregelatinised maize starch sodium laurilsulfate tekprint black sw-9008 tekprint black sw-9010 titanium dioxide - strattera is indicated for the treatment of attention-deficit/hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older and adolescents.

New Zealand - English - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - atomoxetine hydrochloride 91.42mg equivalent to 80 mg atomoxetine free base - capsule - 80 mg - active: atomoxetine hydrochloride 91.42mg equivalent to 80 mg atomoxetine free base excipient: dimeticone gelatin   iron oxide red iron oxide yellow pregelatinised maize starch sodium laurilsulfate   tekprint black sw-9008   tekprint black sw-9010   titanium dioxide   - strattera is indicated for the treatment of attention-deficit/hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older and adolescents.